Updated:
ENDONOVO THERAPEUTICS, INC.
Alan Collier leads Endonovo Therapeutics, a publicly traded company commercializing the FDA-cleared SofPulse device for post-operative pain.
ENDONOVO THERAPEUTICS, INC.
Endonovo Therapeutics was organized in 2018 as a publicly traded company with Collier as its chairman and CEO, succeeding a prior entity that had traded on the OTC market. The firm does not operate as a traditional fund or family office. It is a micro-cap operating company that acquires and commercializes medical devices, functioning as a centralized vehicle for a single regenerative-medicine platform. Its history reflects the classic small-cap pivot: a former shell acquired an FDA-cleared asset and restructured the public entity around that one product. The firm's strategy centers on commercializing SofPulse, a pulsed electromagnetic field (PEMF) device cleared by the FDA for palliative treatment of post-operative pain and edema. Endonovo sells directly and through distributors to hospitals, clinics, and post-acute care facilities in the United States. The geographic footprint remains domestic, with distribution concentrated in North America. The company occasionally explores acquiring complementary non-invasive therapeutic devices, but its deployment to date has been a single-product build-out rather than a diversified portfolio approach. No recent closed-end fund raises or large-scale capital deployments are publicly recorded. The firm's scale is measured by its public-market capitalization and top-line device revenue rather than by assets under management or committed capital. In the last 24 months, Endonovo has focused on expanding SofPulse distribution agreements with regional medical-supply distributors and generating recurring consumable revenue from single-use treatment coils. The company does not operate a philanthropic foundation, a real-asset arm, or any disclosed club-investment vehicle. The firm's structural differentiator is its status as a publicly listed operating company in a space — evidence-based PEMF therapy — that is otherwise dominated by private medical-device startups and wellness-industry players. This gives family offices and institutional allocators a liquid, SEC-reporting vehicle for diligence on a single FDA-cleared device. The governance structure is led solely by Collier, concentrating strategic and operating authority in one principal, which is unusual relative to the typical multi-founder board structure of health-tech startups.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Principals
Alan Collier
Chairman and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Endonovo Therapeutics?
Alan Collier, as Chairman and CEO, holds sole authority over capital allocation and acquisition decisions. The board is small and closely aligned with management, so material transactions are typically originated and negotiated by Collier. Because the firm is a micro-cap operating company rather than a fund, there is no investment committee in the traditional allocator sense.
Is Endonovo Therapeutics structured as a single family office or does it operate more like a venture firm?
Neither. Endonovo is a publicly traded operating company that owns and commercializes an FDA-cleared medical device. It does not manage third-party capital or function as an investment vehicle for a single-family fortune. Its closest structural analog is a single-product medical-device platform company.
Does Endonovo participate in fund commitments or only direct deals?
Endonovo does not make fund commitments. Its deployment model is direct acquisition and commercialization of therapeutic devices, and it has not disclosed any portfolio of passive limited-partner positions. Potential acquisitions would be evaluated as operating-platform add-ons, not as financial investments.
What investment stages does Endonovo typically target?
The company targets FDA-cleared or late-clinical-stage therapeutic devices that can be commercialized through its existing distribution relationships. This is not a venture-capital stage strategy — it acquires assets that have completed the regulatory pathway and are ready for commercial scaling.
What is the underlying wealth behind Endonovo?
There is no disclosed single-family wealth origin. Endonovo was organized via a reverse merger and is funded through public equity markets and, historically, convertible debt. No named family or individual provided seed capital in a disclosed SFO-to-public-company migration. The vehicle is market-funded, not family-funded.
Does Endonovo have meaningful recurring revenue from its device platform?
Yes. SofPulse generates recurring revenue from single-use disposable treatment coils that must be replaced for each therapy session. The hardware itself is sold as a capital-equipment unit, but the consumable coils create a razor-and-blade revenue model that the firm publicly emphasizes as a key economic differentiator.
Which sectors does Endonovo explicitly avoid?
Pharmaceutical development, biologics, and surgical robotics are outside its disclosed scope. The firm's strategy is constrained to non-invasive, electroceutical devices that carry FDA clearances rather than approvals, focusing on pain management and inflammation reduction. It has not disclosed any interest in consumer wellness devices or unregulated therapeutic products.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: